• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

D’Andrea Takes the Reins at Catalyst for Payment Reform

Article

Guy D'Andrea, MBA, has been named the new executive director of the Catalyst for Payment Reform.

Guy D'Andrea, MBA, has been named the new executive director of the Catalyst for Payment Reform.

Guy D’Andrea, MBA, is succeeding Suzanne Delbanco as executive director of the Catalyst for Payment Reform (CPR), a nonprofit payers’ group established to reorient U.S. healthcare away from fee-for-service payment to systems are supposed to reward value over volume and intensity.

D’Andrea is a healthcare industry veteran who has held jobs at predecessor organization to AHIP, the trade association for the health insurance industry, and URAC, the accrediting organization. He founded Discern Health, a health economics and outcomes research consulting firm in 2004, according to a press release from CPR about this selection and sold it to Real Chemistry in 2020.

Most recently, D’Andrea has been the entrepreneur-in-residence at Healthworx, the innovation and investment arm of CareFirst Blue Cross Blue Shield, a Blues plans with members in Maryland and Washington, D.C.

Suzanne Delbanco, the founding exeuctive director of the Catalyst for Payment Reform.

Suzanne Delbanco, the founding exeuctive director of the Catalyst for Payment Reform.

Delbanco was the executive director of CPR since its founding in 2009 until moving to a part-time role as a strategic advisor in February 2023. She has been a visible advocate for, and explainer of, value-based payment and was interviewed often by journalists. In interview with Managed Healthcare Executive earlier this year, Delbanco was asked about the disruptive effects of value-based care and payment.

“If the question is, has it disrupted providers and payers, I think the answer is yes. Has it disrupted the outcomes we were hoping for, meaning has it significantly improved quality or saved money? The answer is no,” Delbanco said.

Andréa Caballero and Ryan Olmstead will continue to serve as the organization’s interim co-executive directors until D’Andrea’s official start date on Aug. 28, the press release says.

The CPR website lists the Peterson Center for Healthcare, The Commonwealth Fund and the New York State Health Foundation as funders. It is also supported by membership fees. According to the organization’s website, the members include private employers, public purchasers, state-based health insurance exchanges, organizations that buy healthcare coverage for multiple employers (union-sponsored health plans) and benefit consulting firms. Members must receive two-thirds or more of their revenue or funding from sources other than the health care industry.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.